E26 transformation-specific (ETS) gene family contains a common DNAbinding domain, the ETS domain, responsible for sequence-specific DNA recognition on target promoters. The Fli-1 oncogene, a member of ETS gene family, plays a critical role in hematopoiesis and is overexpressed in diverse hematological malignancies. This ETS transcription factor regulates genes controlling several hallmarks of cancer and thus represents an excellent target for cancer therapy. By screening compounds isolated from the medicinal plant Dysoxylum binectariferum in China, we identified two chemically related flavagline-like compounds including 4 0 -demethoxy-3 0 ,4 0 -methylenedioxyrocaglaol and rocaglaol that strongly inhibited Fli-1 transactivation ability. These compounds altered expression of Fli-1 target genes including GATA1, EKLF, SHIP1, and BCL2. Consequently, the flavagline-like compounds suppressed proliferation, induced apoptosis, and promoted erythroid differentiation of leukemic cells in culture. These compounds also suppressed erythroleukemogenesis in vivo in a Fli-1-driven mouse model. Mechanistically, the compounds blocked c-Raf-MEK-MAPK/ERK signaling, reduced phosphorylation of eukaryotic translation initiation factor 4E (eIF4E), and inhibited Fli-1 protein synthesis. Consistent with its high expression in myelomas, B-cell lymphoma, and B chronic lymphocytic leukemia (B-CLL), pharmacological inhibition of Fli-1 by the flavagline-like compounds or genetic knock-down via shRNA significantly hindered proliferation of corresponding cell lines and patients' samples. These results uncover a critical role of Fli-1 in growth and survival of various hematological malignancies and point to flavagline-like agents as lead compounds for the development of anti-Fli-1 drugs to treat leukemias/lymphomas overexpressing Fli-1.
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Introduction
Leukemia is the sixth leading cause of cancer death in the United States [1] . While chemotherapy and radiotherapy are the major treatments for leukemia, a growing number of targeted drugs are being developed to treat patients that do not respond to these conventional therapies.
The ETS-related transcription factor (TF) Fli-1 was first identified through retroviral insertional mutagenesis in Friend murine leukemia virus (F-MuLV)-induced erythroleukemias [2, 3] . Continuous expression of Fli-1 in erythroblasts promotes tumorigenesis by blocking differentiation, whereas downregulation of this TF via siRNA in erythroleukemia cells results in growth arrest, differentiation, and apoptosis [4] . Fli-1 abnormal expression was detected in various hematological and solid tumors [5] . It is also involved in translocation in 85% of Ewing's sarcomas, resulting in generation of EWS-FLI1 fusion protein with potent oncogenic activity [6] . Moreover, expression of Fli-1 is required for endothelial survival and angiogenesis, a process that accelerates cancer progression [7] .
In addition to cancer, Fli-1 plays a critical role in hematopoiesis and stem cell maintenance through regulation of several key genes that govern these processes [5, 8] . BCL2, EKLF, cKIT, SHIP1, and GATA1 are among known target genes regulated by Fli-1 [9] [10] [11] [12] [13] [14] . Indeed, targeting Fli-1 during embryogenesis results in early lethality associated with severe defect in hematopoiesis and vasculogenesis [7, 15] . Hemizygous loss of Fli-1 function is the main cause of thrombocytopenia in patients with Paris Trousseau syndrome [16, 17] . Fli-1 expression is also critical for B-cell development and its overexpression promotes autoimmune Lupus in mice [15, 18, 19] . Downregulation of Fli-1 expression in fibroblasts is also implicated in systemic sclerosis [20, 21] . Thus, Fli-1 plays important roles in inducing and promoting cancers and immune-related diseases; the development of Fli-1 inhibitors and agonists may offer novel therapeutic modalities for these disorders.
In recent years, different screening strategies have been employed to identify inhibitors of Fli-1 and EWS-FLI1. These studies led to identification of several small molecules/compounds targeting both DNAand RNA-binding activity of Fli-1 [22] [23] [24] [25] [26] . Our group has recently identified a class of Fli-1 agonists that exhibit strong anticancer activity in vitro and in vivo [27] . We demonstrated that these Fli-1 agonists do not block erythroid differentiation, while they promote megakaryocytic differentiation of erythroleukemic progenitors, resulting in strong anticancer activity in vivo [27] . In the current study, through screening compounds isolated from medicinal plants in China, we identified two novel inhibitors 4 0 -demethoxy-3 0 ,4 0 -methylenedioxyrocaglaol and rocaglaol with flavaglinelike structures that suppressed Fli-1 and EWS-FLI1 transactivation activity. Treatment of erythroleukemic cells with these compounds resulted in Fli-1 protein downregulation through inhibition of c-Raf-MEK-MAPK/ERK signaling and additionally inhibited phosphorylation of eukaryotic translation initiation factor 4E (eIF4E). These compounds suppress proliferation of several human leukemic cells expressing Fli-1 in culture and strongly inhibit leukemogenesis in vivo. Thus, this class of flavagline-like compounds provides a new treatment for cancers overexpressing Fli-1.
Results

Identification of natural anti-Fli-1 flavagline-like compounds from a library of medicinal plants in China
We previously used the plasmid FB-Luc, containing two Fli-1 binding sites cloned upstream of the pGL4.28 reporter gene, to screen for drugs with strong anti-Fli-1 transactivation activity [26] . While this screening led to identification of compounds with antiFli-1 activity, their lack of specificity prompted us to screen for agents with less off-target toxicity. To this end, we used a Fli-1 transcriptional reporter luciferase assay to screen a library of 2000 compounds isolated from medicinal plants commonly used in traditional Chinese medicine. We identified several Fli-1 inhibitory compounds including 4 0 -demethoxy-3 0 ,4 0 -methylenedioxyrocaglaol (A1544) and rocaglaol (A1545), which were derived from plant Dysoxylum binectariferum (Fig. 1A) . Both compounds belong to the flavagline family of natural products and are closely related to rocaglamide (RocA; Fig. 1A ). RocA was shown to possess potent anticancer activity, but the connection to Fli-1 status is not known, nor do we fully understand its underlying mechanism [28] [29] [30] . A1544 and A1545 inhibited luciferase activity of FB-Luc driven by Fli-1 or EWS-FLI1 in a dose-dependent manner (Fig. 1B,C ) but exhibited marginal effect on control CMV-Luc reporter gene (Fig. 1D ). These natural compounds inhibited the growth of erythroleukemia cell lines (CB7, HEL), human myelogenous leukemia cell line (K562), B-cell Burkitt lymphoma cell line (Daudi), and multiple myeloma cell lines (MM.1S and RPMI8226) in culture with low IC50 concentrations ranging 30-157 nmolÁL À1 (Fig. 1E) . RocA, analyzed in parallel, exhibited similar level of antileukemic activity (Data not shown). All these cell lines with exception of K562 expressed high levels of Fli-1 (Fig. 1F) . Interestingly, K562 exhibited the highest IC50 compared to the other lines, indicating somewhat dependency of these compounds on the status of Fli-1.
A1544 and A1545 flavaglines block proliferation and induce apoptosis in leukemia cells
Treatment of erythroleukemia HEL cells with A1544 or A1545 (1 lM) for 24 h resulted in a dose-dependent growth suppression ( Fig. 2A) , which was accompanied by an increased G0/G1 and decreased S phase of cell cycle (Fig. 2B ). Longer treatment of cells with these compounds (3-4 days) resulted in appearance of apoptotic cells in culture (Fig. 2C) . Induction of apoptosis was identified by FITC Annexin V and PI double staining, as revealed by flow cytometry, A1544 and A1545 increased apoptosis in HEL cells 48 h postdrug treatment (Fig. 2D) . Besides, western blot showed A1544 or A1545 treatment led to downregulation of antiapoptotic protein BCL2, a direct target of Fli-1 [12] , upregulation of proapoptotic protein Bax, activation of caspase 9, caspase 3, and PARP1 (Fig. 2E) . Similar growth suppression and apoptosis phenotype were seen in CB7 cells treated with A1544 and A1545 (Figs S1 and S2).
Fli-1 inhibition by A1544 or A1545 flavaglines induces erythroid differentiation erythroleukemic cells
Exogenous Fli-1 expression in erythroid progenitors was previously reported to block erythroid differentiation [31] [32] [33] [34] . In contrast, shRNA downregulation of this TF promoted apoptosis and erythroid differentiation [4] . To determine the effect of A1544 and A1545 on differentiation, we examined several Fli-1 target genes involved in this process. In HEL cells, A1544 or A1545 treatment increased mRNA expression of EKLF, SHIP1, and GATA1 (Fig. 3A,B) , the three known target genes negatively regulated by Fli-1 [30] [31] [32] [33] [34] [35] . These compounds also increased mRNA levels of the erythroid-specific differentiation genes p45 NFE2 and b-globin. Since HEL cells can differentiate into both erythroid and megakaryocytic cells by different inducers, these compounds showed no effect on expression of the megakaryocytic-specific marker gene PF4 (Fig. 3A,  B) . Compound-treated cells also expressed a higher level of the cyclin-dependent kinase inhibitor p27 kip1 , which is known to be induced only during erythroid differentiation [36] . Expression of p21 cip1 is exclusively induced during megakaryocytic differentiation [36] . While A1544 and A1545 had no significant effect on p21 cip1 expression (Fig. 3C) , a higher level of this cell cycle inhibitor was detected when HEL cells were forced to undergo megakaryocytic differentiation by the Fli-1 agonist TPA [25] . However, TPA was unable to induce p27 kip1 or p45 NFE2 expression in these cells (Fig. 3C ). Flow cytometry analysis showed that while TPA induced the megakaryocytic marker CD41 in HEL cells, A1544 and A1545 only induced expression of the erythroid differentiation markers CD71 and GPA (CD235a; Fig. 3D ). These results demonstrate that A1544 and A1545 stimulate erythroid differentiation but have no significant effect on megakaryocytic differentiation (see model, Fig. 3E ).
A1544 and A1545 flavaglines downregulate Fli-1 expression posttranscriptionally
To uncover the mechanism of Fli-1 inactivation by A1544 and A1545, we first examined their effects on fli-1 mRNA levels. Paradoxically, we found that both compounds induced higher fli-1 mRNA levels in HEL cells (Fig. 4A ). In erythroleukemic CB7 cells, A1544 had no effect, whereas A1545 slightly increased fli-1 mRNA expression (Fig. 4B ). Since both A1544 and A1545 significantly downregulated Fli-1 protein levels in HEL and CB7 cells (Fig. 4C,D) , these compounds may reduce Fli-1 protein expression posttranscriptionally, and the observed increase in fli-1 mRNA is likely due to negative autoregulation. Indeed, the promoter of fli-1 contains several E26 transformation-specific (ETS) binding sites [37, 38] . A recent study showed that inhibition of the bromodomain and extraterminal (BET) protein BRD4, a component of chromatin remodeling, suppresses transcription of Fli-1 and several other important hematopoietic TFs in acute myeloid leukemia (AML) [39] . We found that both A1544 and A1545 significantly upregulated BRD4 expression (Fig. 4E ). This effect may therefore account for the higher fli-1 mRNA expression induced by these two flavagline compounds. The protein synthesis inhibitor cycloheximide (CHX) did not significantly decrease Fli-1 expression after A1544 and A1545 treatment (Fig. 4F) , implying that A1544 and A1545 inhibit new protein synthesis. These data suggest that A1544 and A1545 decrease Fli-1 expression through posttranscriptional protein synthesis inhibition.
A1544 and A1545 flavaglines inhibit MAPK/ERK pathway leading to apoptosis and erythroid differentiation
To probe for the posttranslational mechanism that affects Fli-1 protein levels in response to A1544 and A1545, we examined and ruled out proteasomal inhibition (Fig. S3) , miR-145 [40, 41] (Fig. S4) , and ribosomal biogenesis [42] (Fig. S5) . During cell proliferation, binding of PHB1/PHB2 dimer to c-Raf generates a complex that activates MAPK/ERK. This kinase then activates MNK1 that increases protein synthesis through phosphorylation of the downstream eIF4E [43] . This pathway, which promotes CAP-dependent mRNA translation [44] , is disrupted by RocA-mediated inhibition of prohibitin [45] . Given the structural similarity between A1544/A1545 and RocA (Fig. 1A) , we investigated whether these two compounds inactivate this pathway, as previously reported for RocA [45, 46] . In HEL cells, A1544 or A1545 treatment significantly reduced the expression of phosphorylated c-Raf, MEK, ERK and the target of the MNK1 kinase eIF4E (Fig. 5A,B) . PHB2 protein expression was not significantly affected (Data not shown). As a contrast, the MNK1-specific inhibitor CGP57380 blocked the phosphorylation of eIF4E. The MEK inhibitor U0126 blocked Fli-1 and the phosphorylation of eIF4E and ERK. This suppression was not . In contrast, TPA blocks erythroid differentiation and promotes megakaryocytic maturation through activation of Fli-1(↑) and downstream gene p21 cip1 and lineage markers CD41/CD61, as described [27] .
observed following treatment with the p38 inhibitor SB203580 or JNK inhibitor SP600125 (Fig. 5B) . These results suggest that A1544 and A1545 downregulate Fli-1 at least partly through MAPK/ERK pathway while not through p38 or JNK pathway. Similar results were seen in CB7 cells treated with A1544, A1545 or RocA (Fig. S6) . Interestingly, expression of survivin protein is downregulated by the compounds and CGP57380 (Fig. 5C ). This data suggests that survivin translation may regulated by phosphorylation of eIF4E, independent of Fli-1. A model for how the flavagline compounds affects Fli-1 and downstream regulatory genes, leading to growth suppression is depicted in Fig. 5D . In human erythroleukemia HEL cells, transduced with a Fli-1 shRNA or control scramble lentivirus (Fig. 6A) , Fli-1 downregulation (Fig. 6B ) resulted in significant inhibition of growth (Fig. 6B) , induction of apoptosis (Fig. 6C) , and downregulation of important target gene BCL2 [12] (Fig. 6D) . Downregulation of Fli-1 in HEL cells also significantly increased the IC50 of both A1544-and A1545-treated cells indicating that Fli-1 downregulation weakens the survival sensitivity of these cells to A1544 and A1545 treatment (Fig. 6E) . Notably, the IC50 of transduced HEL cells (Fig. 6E ) was higher than normal cells (Fig. 1E) . This difference is likely due to the fact that the transduced cells were treated for 2 weeks with puromycin for gene selection. While erythroleukemia is considered very rare among human hematological malignancies, high Fli-1 expression is observed in other hematopoietic cells [5] . Using cBioPortal analysis (http://www.cbioportal.org/ index.do) [47, 48] , we detected high fli-1 mRNA expression in diffuse large B-cell lymphoma (DLBC), AML, and thymoma patients (Fig. 7A) . We confirmed robust Fli-1 protein expression in the human-derived multiple myeloma cell lines RPMI8226, MM.1S, and Daudi (Fig. 1F) . Both A1544 and A1545 blocked proliferation of these cell lines, and this was associated with downregulation of phosphorylated eIF4E, Fli-1, and BCL2 (Fig. 7B-D) . To further confirm the role of Fli-1 in proliferation of these leukemic cell lines, HEL, RPMI8226, MM1.S, and Daudi were infected with Fli-1 shRNA lentivirus particles. Fli-1 knockdown in RPMI8226, MM1.S, and Daudi cells (Fig. 7E-G) resulted in significant inhibition of proliferation when compared to control. Moreover, in cells isolated from three patients with B-chronic lymphocytic leukemia (B-CLL; Table S3 ), both compounds inhibited Fli-1 and led to significant loss of viability ( Figs 7H and S7 ). These results demonstrate potent effects of A1544 and A1545 or Fli-1 knockdown on proliferation of various hematological malignancies in vitro.
A1544 and A1545 flavaglines inhibit leukemogenesis in a mouse model of leukemia overexpressing Fli-1
To determine the effect of A1544 and A1545 flavaglines on cancer progression we used a model of FMuLV-induced erythroleukemia in which insertional activation of Fli-1 initiates leukemogenesis [26] . Erythroid transformation usually occurs as early as 30 days post viral injection [49] . At 6 weeks postviral infection, low doses of A1544 or A1545 were injected to the mice at 3 mgÁkg À1 every other day for a total of six treatments. This short treatment resulted in a significant inhibition of erythroleukemia development with A1544 having a stronger suppression effect than A1545 (Fig. 8A) . We observed significantly higher hematocrit reading in mice treated with A1545 than control, but less significant with A1544-treated mice (Fig. 8B ). This may be due to increased erythroid differentiation induced by A1545 (Fig. 3) . Indeed, when tumorigenic spleens from these mice were examined for hematopoietic cells, a significantly higher number of splenocytes expressing erythroid-specific markers CD71 and TER119 were found in leukemic spleens of A1545-treated mice compared with DMSO-injected controls (Fig. 8C,D) . Moreover, expression of phosphorylated eIF4E, BCL2, and Fli-1 was much lower in three individual A1545-treated tumors (group 1-3) compared to the corresponding control (Fig. 8E) . Both control and drug treated mice showed similar size of spleen at end point due to massive leukemic cells infiltration into this organ (Fig. 8F) . These results demonstrate potent antileukemic effect of A1544 and A1545 flavaglines in vivo.
Discussion
Fli-1 frequently alters in malignancies and regulates various hallmark of cancer including proliferation, differentiation, apoptosis, angiogenesis, genomic stability, and inflammation [5, 50] . Fli-1 thus emerges as a powerful target for cancer therapy. Using a library of compounds isolated from medicinal plants we now identified two compounds with potent antileukemic activity in culture and in vivo. In erythroleukemic cells whose survival and proliferation depends on the expression of this TF, these compounds alter expression of Fli-1 downstream targets leading to the induction of apoptosis and erythroid differentiation. In other hematological malignancies, Fli-1 downregulation by these compounds or shRNA significantly repressed proliferation. Downregulation of Fli-1 protein by these compounds revealed to be mediated through translational mechanisms involving c-Raf-MEK-MAPK/ERK pathway. These compounds then can be used for treatment of various leukemias and lymphomas expressing Fli-1. Erythrocytes and megakaryocytes were derived from a common megakaryocytic and erythroid progenitor (MEP) [10, [51] [52] [53] . Fli-1 high or low expression is shown to play a critical role in commitment of MEP to become megakaryocytes or erythrocytes, respectively [10, 52] . We previously showed that Fli-1 agonist compounds induced a megakaryocytic differentiation program in erythroleukemic cells by upregulating megakaryocytic-specific target genes, leading to leukemic inhibition [27] . Data in this study also revealed that drug-mediated Fli-1 inhibition resulted in a strong anti-leukemic effect, through induction of erythroid differentiation. This was shown to be mediated through Fli-1 target genes (EKLF, SHIP1, and GATA1). These results indicate that compounds capable of both activation and inactivation of Fli-1 could have potent antileukemic effect in erythroid/megakaryocytic-derived leukemias.
Downregulation of Fli-1 protein by A1544 and A1545 compounds resulted in significant increase in transcription of fli-1. This result raised possibility of Fli-1 autoregulation at the promoter level. Indeed, Fli-1 transcription is controlled by two promoters carrying binding sites for several transcription factors including ETS-binding proteins. ETS-1 and Spi-1/PU.1 are known to bind and activate the fli-1promoter [37, 38] . The increase in transcription of fli-1 followed by a decrease in protein expression by the compounds supported a negative loop mechanism of gene regulation by this TF, which may need further investigation in another independent study. The natural compound RocA that is structurally related to A1544 and A1545, inhibits the c-Raf-MEK-MAPK/ERK pathway by targeting PHB1/PHB2 [45, 46] . Inhibition of PHB/c-Raf complex activity by RocA blocks MAPK/ERK signaling leading to suppression of tumor growth. Similarly, A1544 and A1545 compounds suppressed this pathway and for the first time revealed to suppress proliferation in part through downregulation of Fli-1 (see model, Fig. 5D ). RocA is also reported to suppress translation initiation through inhibition of MNK1 and downstream phosphorylation of eIF4E, an effect that was similarly detected within our compounds [43] . Thus, our compounds and RocA likely exert their anticancer activity in part through translational suppression of Fli-1.
The compounds inhibited growth of the Fli-1-negative cell line K562 but at a higher IC50 than Fli-1-expressing cells. We also found A1544 and A1545 compounds did not reduce the level of phosphorylated ERK in K562 (Data not shown). This result indicates a possible off-target activity or other mechanisms of these agents in Fli-1-negative leukemia cells.
Consistent with this observation, downregulation Fli-1 in erythroleukemic cells significantly increased IC50 after treatment with the compounds. While the off-target activity of the compounds still remain to be determined in future studies, expression of survivin is shown to be inhibited by the compounds independent of Fli-1. Moreover, a recent report also revealed the ability of RocA to inhibit the function of eIF4A [54] . Thus, this compound inhibits the function of eIF4E and eIF4A, components of cap binding complex. Whether eIF4A regulates target proteins distinct from eIF4E, remains to be determined.
Fli-1 expression is detected in most hematopoietic cells as well as other types of cancer [5] . In both human and mouse erythroleukemias, Fli-1 downregulation by siRNA leads to growth inhibition and apoptosis [4] . Here, we showed for the first time a growth inhibition effect of Fli-1 downregulation by shRNA genetic knock-down in other human hematological malignancy derived cell lines including myeloid, B-cell lymphomas, erythroleukemia, and patients with B-CLL. Both A1544 and A1545 also . RE was determined by measuring band intensity using densitometry. These experiments were repeated three times.
inhibited growth of these cells associated with downregulation of Fli-1 and its target gene BCL2. Antiapoptotic protein BCL2 is a member of BCL2 family proteins that serves a crucial role in modulation of apoptosis. This observation reveals that Fli-1 expression plays a critical role in a variety of hematological malignancies. Thus, inhibition of Fli-1 represents an important strategy to cure cancers overexpressing this TF. In Friend leukemia model where Fli-1 plays a critical role during initiation of erythroleukemia, A1544 and A1545 compounds significantly delayed leukemogenesis, even with a short period of treatment. This inhibition was associated with increased erythroid differentiation in leukemic spleens. These compounds exhibited no toxicity as this group of chemical agents was shown to selectively target cancer cells with genomic abnormality [55] . This result further supports the efficacy of this class of compounds and their derivatives for treatment of leukemias expressing Fli-1.
In conclusion, using compound screening strategy we identified potent inhibitors of Fli-1. These inhibitors of the flavagline family, were shown to suppress expression of Fli-1 by a posttranslational mechanism involving suppression of translational initiation through the c-Raf-MEK-MAPK/ERK pathway and inhibit eIF4E phosphorylation. These natural flavagline compounds provide potentially new modality to treat diverse types of leukemia.
Materials and methods
Cell lines
Murine Friend virus-induced erythroleukemic cell lines CB7 and CB3, human erythroleukemic cell line HEL, human myelogenous leukemia cell line K562, human Bcell Burkitt lymphoma cell line Daudi, human multiple myeloma cell lines MM.1S and RPMI8226, as well as human embryonic kidney HEK293T cell line were maintained in RPMI supplemented with 5% fetal bovine serum (Hyclone, GE Healthcare, Pittsburgh, PA, USA). Human B-CLL cells were isolated and grown as described previously [56] . 
Tumor induction and in vivo compound treatment
Viral supernatants from NIH-3T3 cells transduced with FMuLV clone 57 plasmid were harvested and frozen at À80°C. New born mice were inoculated by intraperitoneal F-MuLV injections, as described [26] . Five weeks postinfection, leukemic mice were injected intraperitoneally, every other day with a total of six injections of A1544 and A1545 compounds (3 mgÁkg À1 of bodyweight) or DMSO as vehicle control and monitored for signs of disease, as previously described [27] . Mice showing signs of late-stage disease were sacrificed, spleens were removed and weighted, hematocrits were determined, and survival was determined, as described [26] .
Cell proliferation
The cell proliferation was analyzed by MTT assay. Cells (5 9 10 3 /well) were seeded in 96-well plates and treated with A1544 and A1545 at different concentrations for indicated hours. After treatment, the absorbance was detected using a Synergy2 modular Multi-Mode Reader (BioTek, Winooski, VT, USA) at 490 nm.
Flow cytometric analysis
Immunofluorescence staining was performed to determine expression of various molecules on the cell lines, tumors cells of drug-treated and control (DMSO treated) mice, as described [27] . In brief, 1 9 10 6 cells were incubated with CD16/CD32 blocking antibody or human Fc receptorbinding inhibitor (eBioscience, San Diego, CA, USA) for 20 min, then stained with primary antibodies for 30 min on ice. Primary antibodies were as follows: human CD41-FITC, mouse CD41-FITC, mouse CD61-APC, human CD71-APC, mouse CD71-APC, mouse TER119-FITC and human CD235a-PE (eBioscience). Then cells were washed and resuspended in 500 lL of phosphate buffered saline. A total of 1 9 10 4 events were collected using the FACS Calibur flow cytometer (BD Biosciences, Franklin lakes, NJ, USA) and analyzed using CELLQUEST PRO software (BD Biosciences). 
Apoptosis and cell cycle analysis
Drug screening and luciferase assay
A library of 1500 compounds, isolated from medicinal plants in China, was used to screen for anti-Fli-1 activity, as previously described [26, 27] . In brief, HEK293T cells were cotransfected with FB-Luc (1.25 lg) and expression vector MigR1-Fli-1 (1.25 lg), MSCV-EWS-FLI1 (1.25 lg), or CMV-Luc (1.25 lg) for 24 h using Lipofectamine 2000 (Life Technology, Beijing, China) following the manufacturer's protocol. The Fli-1 binding site was cloned into the pGL4.28 luciferase reporter plasmid containing a minimal promoter, designated FB-Luc. The transfected cells were plated into 96-well plates and then treated with indicated compounds. Luciferase activity was determined 34 h posttransfection using the luciferase assay system (Promega, Mannheim, Germany), as described [27] . Lead anti-Fli-1 compounds were chosen for their ability to reduce luciferase activity by at least 50%.
Western blot
Western blot was conducted as described [26] . Polyclonal rabbit antibody for Fli-1, eIF4E, phosphorylated eIF4E, NOLC1, and NOL6 were obtained from Abcam (Abcam, Cambridge, UK); Bax, Caspase 9, Caspase 3, PARP1, Survivin, c-Raf, phosphorylated c-Raf, MEK, phosphorylated MEK, ERK, and phosphorylated ERK were obtained from Cell Signaling Technology (CST, Danvers, MA, USA); GAPDH was obtained from Sigma (Sigma Aldrich, Shanghai, China); b-actin, BCL2 were obtained from Proto-Technology (Protein-Tech, Bucuresti, Romania). The dilution of antibodies was used according to the manufacturer instructions. Images were acquired by Odyssey Platform (LI-COR Biosciences, Lincoln, NE, USA). The inhibitors of MEK (U0126), JNK (SP600125), MNK1 (CGP57380), and p38 (SB203580) were all obtained from Sellectchem (Sellectchem, Houston, TX, USA). CHX was obtained from ApexBio (ApexBio, Houston, TX, USA). These compounds were dissolved in DMSO and added to the cells at indicated concentration, as described in the results section.
Quantitative real-time PCR
RNA levels were determined by quantitative real-time PCR (Q-RT-PCR) in a StepOne Plus thermal cycler (Applied Biosystems, Forest city, CA, USA) using specific primers and SYBR Ò select Master Mix (Life technologies, Carlsbad, CA, USA) as described [57] . The GAPDH gene was used as control, the list of primers used for RT-PCR and Q-RT-PCR are shown in Table S1 .
Cloning and viral infection
The Fli-1 shRNA construct (Fli-1 shRNA) was generated by synthesizing Fli-1 shRNA (Vigene Bioscience, Shandong, China) and cloning into the BcuI sites of PLent4inshRNA-GFP plasmid (Vigene Bioscience, Rockville, MD, USA). The sequence of Fli-1 shRNA is shown in Table S2 . For lentivirus production, Fli-1 shRNA expression plasmid and packaging plasmids psPAX2 and pMD2.G (a gift from Didier Trono, Addgene plasmid #12259 and #12260) were cotransfected into HEK293T cells, as described [27] . Forty-eight hours posttransfection, the supernatants were harvested and were centrifuged at 1000 9 g for 10 min, then filtered through 0.45 lm filters. The viral supernatants were either used for infection freshly or stored at À80°C. For cell infection, HEL, Daudi, MM.1S, and RPMI8226 cells were cultured and grown in the presence of fresh supernatant of lentivirus producing cells. After 24 h infection, medium was changed, and cells were grown in the presence of puromycin (Solarbio, Beijing, China), until puromycin-resistant cells were obtained.
CBioPortal analysis
CBioPortal analysis for Fli-1 expression was depicted from the website www.cbioportal.org. The portal currently contains data from 159 cancer genomics studies [47, 48] . The data presented in Fig. 7A are profiles of genetic changes depicted from selected cancer genomic studies.
Survival and statistical analysis
The mouse survival rates were computed and plotted according to the nonparametric Kaplan-Meier analysis. Statistical analysis was performed using the two-tailed Student's t-test with significance considered at P < 0.05, and by analysis of variance using ORIGIN 3.5 software (Microcal Software, Northampton, MA, USA).
Animal care
Animal care was in accordance with the guidelines of the institution, animal care committee and Guizhou Medical University.
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